SignalRx Pharmaceuticals (United States)

Recent papers from SignalRx Pharmaceuticals (United States)

1. PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic LeukemiaBlood Cancer Discovery · 2025
2. LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studiesBiomedical Chromatography · 2023
3. Nitric Oxide: The Missing Factor in COVID-19 Severity?Medical Sciences · 2021
4. Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaFrontiers in Oncology · 2021
5. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphomaiScience · 2021
6. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor2021
7. Covid-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges (Russian Translation)Juvenis scientia · 2021
8. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and ChallengesTheranostics · 2020
9. Amino Acids Regulate Cisplatin Insensitivity in NeuroblastomaCancers · 2020
10. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicityCell Discovery · 2020
11. Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targetsScientific Reports · 2020
12. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerMolecular Cancer Therapeutics · 2019
13. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune SystemJournal of Oncology · 2019
14. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replicationJournal of Biological Chemistry · 2018
15. Controlled self-assembly of glycoprotein complex in snail mucus from lubricating liquid to elastic fiberRSC Advances · 2018
16. Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasisProceedings of the National Academy of Sciences · 2017
17. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126Oncotarget · 2016
18. Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular CarcinomaMolecular Cancer Therapeutics · 2016
19. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven MedulloblastomaPLoS ONE · 2016
20. A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and MetastasisMolecular Cancer Research · 2014